TY - JOUR
T1 - The use of systemic and topical fluoroquinolones
AU - COMMITTEE ON INFECTIOUS DISEASES
AU - Jackson, Mary Anne
AU - Schutze, Gordon E.
AU - Byington, Carrie L.
AU - Maldonado, Yvonne A.
AU - Barnett, Elizabeth D.
AU - Campbell, James D.
AU - Davies, H. Dele
AU - Lynfield, Ruth
AU - Munoz, Flor M.
AU - Nolt, Dawn
AU - Nyquist, Ann Christine
AU - O'Leary, Sean
AU - Rathore, Mobeen H.
AU - Sawyer, Mark H.
AU - Steinbach, William J.
AU - Tan, Tina Q.
AU - Zaoutis, Theoklis E.
N1 - Publisher Copyright:
Copyright © 2016 by the American Academy of Pediatrics.
PY - 2016/11
Y1 - 2016/11
N2 - Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.
AB - Appropriate prescribing practices for fluoroquinolones, as well as all antimicrobial agents, are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children has become better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in this report. Prescribing clinicians should be aware of specific adverse reactions associated with fluoroquinolones, and their use in children should continue to be limited to the treatment of infections for which no safe and effective alternative exists or in situations in which oral fluoroquinolone treatment represents a reasonable alternative to parenteral antimicrobial therapy.
UR - http://www.scopus.com/inward/record.url?scp=84994885383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994885383&partnerID=8YFLogxK
U2 - 10.1542/peds.2016-2706
DO - 10.1542/peds.2016-2706
M3 - Article
C2 - 27940800
AN - SCOPUS:84994885383
SN - 0031-4005
VL - 138
JO - Pediatrics
JF - Pediatrics
IS - 5
M1 - e20162706
ER -